Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds.
about
Structural insights into corepressor recognition by antagonist-bound estrogen receptorsStructural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.A novel pesticide-induced conformational state of the oestrogen receptor ligand-binding domain, detected by conformation-specific peptide binding.Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combinationDiarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.Estrogen receptor α/β-cofactor motif interactions; interplay of tyrosine 537/488 phosphorylation and LXXLL motifs.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities.Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease.Multiplexed and microparticle-based analyses: quantitative tools for the large-scale analysis of biological systems.Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptorInhibition of prostate cancer cell growth by second-site androgen receptor antagonists.A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors.Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.
P2860
Q27643750-A043727E-29D8-4402-B6D7-58A97655458BQ30418832-87AAA645-0896-4114-8087-0DE073F5BA7FQ31140418-12AEBE7A-B057-452F-9FE4-945F8D4137CFQ33642558-AD6B4108-74CF-4754-9FDB-B11A2F4ABA1FQ34236388-06A1830F-4C85-470D-801B-81DFD91F149BQ34396913-45B0872C-0D09-4681-B9E8-94EE7DFE6DBCQ34534031-24C840FF-E884-4A2E-AC9F-75B7FFE9603BQ34788711-CABD14B5-22A8-441C-BAF7-0F544ADADC53Q36333338-95E59D61-B84E-42B1-A31B-61B46BC31305Q36384804-6C4CBAC1-EF65-461A-A795-66182824BB83Q36952089-4ED67668-D8F1-42E8-A304-D4E35EE23D8BQ37274341-7B6EAB7E-F2DD-45B1-80BB-62914A90EE84Q38317726-3B999F7A-4336-4214-A902-D470561C0AEAQ39825886-12039AA5-5B76-4C10-88B0-768F39C5BE7FQ41814793-C5246623-C5E6-442B-AB12-DAD2EE1C459A
P2860
Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Correlation between in vitro p ...... receptor-modulating compounds.
@ast
Correlation between in vitro p ...... receptor-modulating compounds.
@en
type
label
Correlation between in vitro p ...... receptor-modulating compounds.
@ast
Correlation between in vitro p ...... receptor-modulating compounds.
@en
prefLabel
Correlation between in vitro p ...... receptor-modulating compounds.
@ast
Correlation between in vitro p ...... receptor-modulating compounds.
@en
P2093
P356
P1476
Correlation between in vitro p ...... receptor-modulating compounds
@en
P2093
Catherine A Simmons
Daniel L Svoboda
Jean Shearin
John G Gray
Kenneth H Pearce
Marie A Iannone
Su-Jun Deng
Sue H Kadwell
Thomas G Consler
P304
P356
10.1210/ME.2003-0432
P577
2004-02-19T00:00:00Z